Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug-eluting coronary artery stent and method for preparing same

A coronary artery and drug technology, applied in the medical field of treating cardiovascular diseases, can solve the problems of LAST and stent poor adherence, hinder the vascular endothelialization on the stent surface, poor biocompatibility, etc. Biocompatible properties, uniform release effect

Inactive Publication Date: 2009-08-26
D PULSE MEDICAL BEIJING CO LTD
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This solution generally has the following problems in use: 1. The DES coated with polymer layer has poor biocompatibility, and it is easy to generate thrombus in the blood vessel for a long time; 2. It is only on the surface of the stent matrix With a polymer layer, it is difficult to slowly release the drug over a long period of time, and the stent matrix (or stent matrix with a polymer layer) after the drug is released will hinder the endothelialization of blood vessels on the surface of the stent, thereby 3. Some materials of the polymer layer loaded with drugs or their degradation products can also cause hypersensitivity and inflammatory reactions; etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug-eluting coronary artery stent and method for preparing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] 300 mg of drug rapamycin (Rapamycin) (dissolved in acetone to form a 10% rapamycin acetone (Acetone) solution) was injected into 300 ml of chitosan acidic aqueous solution. The percentage by weight of each substance in the solution is 3% of chitosan; 2% of acetic acid; 2% of sodium chloride; and 93% of distilled water. (wherein chitosan is a drug microsphere encapsulation material, aqueous acetic acid is a solvent for chitosan, and sodium chloride plays a role in promoting the dissolution of chitosan better), so that the obtained

[0042] Drug / chitosan=12%-18% solution.

[0043] The chitosan acidic aqueous solution was mixed with 3-5 ml of liquid paraffin / ether mixture containing 0.85 g of emulsifier—Sorbitan Sesquioleate (Sorbitan Sesquioleate, Arlacel 83). This mixed liquor is the solvent of emulsifier, and its component weight ratio is

[0044] Liquid paraffin / ether=35 ml / 25 ml.

[0045] The liquid containing chitosan acidic aqueous solution, emulsifier, and drug ...

Embodiment 2

[0048] Drug rapamycin (Rapamycin) 200 mg (dissolved in acetone to form 1% rapamycin acetone (Acetone) solution) was injected into 250 ml chitosan acidic aqueous solution. The percentage by weight of each substance in the acidic solution is 2% chitosan; 1% acetic acid; 97% distilled water. (wherein chitosan is a drug microsphere encapsulation material, and the aqueous acetic acid solution is a solvent for chitosan), so that obtaining

[0049] Drug / chitosan=13%-17% solution.

[0050] The sodium tripolyphosphate (TPP) aqueous solution whose mass concentration is 0.45 mg-1.0 mg / ml is slowly added dropwise to the above-mentioned drug-containing chitosan acetic acid solution under high-speed stirring at 2000 rpm, and the solution is The mass concentration of the chitosan is 0.5 mg-1.0 mg / ml, and the dropping quantity is that the mass ratio of the chitosan acetic acid solution containing the medicine to the sodium tripolyphosphate solution is 5:1-10:1. Control the pH value (PH valu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention provides a drug-eluting coronary artery stent and a method for preparing the same. The method comprises the following steps: providing a basal body for the coronary artery stent; providing a micro arc oxidation treatment device comprising an electrolyte tank; adding an electrolyte into the electrolyte tank and stirring the electrolyte evenly, wherein the formulation of the electrolyte comprises that calcium acetate (CH3COO)2Ca.H2O of which the concentration is between 0.2 and 0.6 mol per liter and sodium dihydrogen phosphate NaH2PO4 of which the concentration is between 0.02 and 0.06 mol per liter are added to 400 milliliters of distilled water respectively; and putting the basal body of the coronary artery stent into the electrolyte, starting the micro arc oxidation treatment device to run for 1 to 12 minutes to obtain the basal body of the coronary artery stent, and then assembling the basal body of the coronary artery stent with microspheres for encapsulating drugs so as to obtain the drug-eluting coronary artery stent. While the drug-eluting coronary artery stent slowly releases the drugs, the drug-eluting coronary artery stent promotes the complete blood vessel endothelialization on the surface of the implanted coronary artery stent for endothelial tissues of normal coronary artery blood vessels to grow on the surface of the implanted stent.

Description

technical field [0001] The invention relates to medical technology for treating cardiovascular diseases, more specifically to a drug-eluting coronary stent (DES) and a preparation method thereof. Background technique [0002] Drug-eluting coronary stents, referred to as drug-eluting stents, have been widely used clinically, and the results show that their curative effect in the treatment of coronary heart disease (coronary stenosis) is definite, and it can significantly reduce intimal hyperplasia and late stage after stenting. Loss of coronary lumen, thereby reducing intra-segment coronary restenosis and target lesion revascularization rate (TLR), which ultimately reduces the incidence of severe and adverse events (MACE), making it the current treatment for coronary artery disease at home and abroad. Stenosis is one of the main means of coronary artery disease. However, with the widespread application of DES, the safety of DES, especially late late stent thrombosis (LAST: L...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61L31/02A61L31/16A61F2/82
Inventor 郑兴仪王征吕向东
Owner D PULSE MEDICAL BEIJING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com